Physician profile
Ashby Kaylin Dellinger
NPI 1285393397
$2,728.09
in general payments reported to CMS, 2019-2025
20 companies · $993 in 2025
The $993 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $345 · 2023: $567 · 2024: $824 · 2025: $993.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,383.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,383.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $547.07 | 2022-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $532.73 | 2022-2025 | |
| Novo Nordisk INC | $432.94 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $272.85 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $189.48 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $170.82 | 2023-2025 | Jardiance, Synjardy |
| Exact Sciences Corporation | $115.19 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $98.87 | 2024-2025 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $74.41 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $51.08 | 2023 | Xifaxan |
| Dexcom, INC. | $46.70 | 2024 | Dexcom G6 Transmitter |
| Pfizer INC. | $38.46 | 2023-2024 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $35.09 | 2022 | |
| Axsome Therapeutics, INC. | $23.90 | 2025 | Auvelity |
| Mylan Specialty L.P. | $21.59 | 2023 | Yupelri |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $18.41 | 2022 | |
| Boston Scientific Corporation | $18.09 | 2025 | Wavewriter Alpha Prime 16 |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.53 | 2025 | Caplyta |
| Novartis Pharmaceuticals Corporation | $12.78 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $12.10 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashby Dellinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.